Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $18.74

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) gapped down prior to trading on Thursday . The stock had previously closed at $18.74, but opened at $18.17. Calliditas Therapeutics AB (publ) shares last traded at $18.41, with a volume of 688 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a research note on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Stock Performance

The firm has a market cap of $557.07 million, a P/E ratio of -11.40 and a beta of 1.50. The stock’s 50 day moving average is $21.08 and its two-hundred day moving average is $20.59. The company has a debt-to-equity ratio of 2.89, a current ratio of 3.13 and a quick ratio of 3.08.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last posted its earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The business had revenue of $42.45 million for the quarter, compared to analysts’ expectations of $36.24 million. Calliditas Therapeutics AB (publ) had a negative net margin of 38.72% and a negative return on equity of 104.47%. During the same quarter in the previous year, the firm posted ($0.01) earnings per share. As a group, equities analysts predict that Calliditas Therapeutics AB will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Optiver Holding B.V. acquired a new position in Calliditas Therapeutics AB (publ) in the fourth quarter valued at about $25,000. Tower Research Capital LLC TRC boosted its position in Calliditas Therapeutics AB (publ) by 1,270.2% in the third quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after buying an additional 3,112 shares in the last quarter. Jane Street Group LLC boosted its position in Calliditas Therapeutics AB (publ) by 7.6% in the third quarter. Jane Street Group LLC now owns 12,491 shares of the company’s stock valued at $191,000 after buying an additional 886 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Calliditas Therapeutics AB (publ) by 26.5% in the first quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock valued at $2,170,000 after buying an additional 18,978 shares in the last quarter. 2.83% of the stock is currently owned by institutional investors and hedge funds.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.